Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMX157 in healthy subjects
NCT02585440Phase 1Completed
- Sponsor
- Hepion Pharmaceuticals
- Start
- Apr 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of tenofovir in hepatitis B infection (HBV) and human immunodeficiency virus infection (HIV) (5 arms), sponsored by Hepion Pharmaceuticals. Primary endpoint: Evaluation of the safety and tolerability of multiple oral doses of CMX157 at increasing dose levels at 28 days. Started Apr 2016; status: completed.
02
Drugs
tenofovir
03
Conditions
hepatitis B infection (HBV)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02585440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02585440.